Mostrar el registro sencillo del ítem
dc.contributor.author
Perez Lloret, Santiago
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Rojas, Gloria Meza
dc.contributor.author
Menoni, Maria Celia
dc.contributor.author
Ruiz, Gabriela
dc.contributor.author
Velásquez, Carolina
dc.contributor.author
Rodriguez, Hernán
dc.contributor.author
Rey, María Verónica
dc.contributor.author
Cardinali, Daniel Pedro
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.date.available
2023-04-20T15:19:48Z
dc.date.issued
2012-01
dc.identifier.citation
Perez Lloret, Santiago; Rojas, Gloria Meza; Menoni, Maria Celia; Ruiz, Gabriela; Velásquez, Carolina; et al.; Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an 8-week treatment course; Lippincott Williams; Clinical Neuropharmacology; 35; 1; 1-2012; 21-24
dc.identifier.issn
0362-5664
dc.identifier.uri
http://hdl.handle.net/11336/194768
dc.description.abstract
BACKGROUND: Pregabalin (PGB) has been shown to improve sleep quality and health-related quality of life (HRQoL) as well as pain intensity in patients with neuropathic pain. OBJECTIVE: The objective of the study was to explore the magnitude of the correlations between changes in pain intensity, sleep quality, and HRQoL after PGB treatment. METHODS: One hundred thirty-eight patients with neuropathic pain of any origin and without an adequate response to analgesics received an 8-week treatment course of PGB in an open-label fashion. Pain intensity, sleep quality, and HRQoL outcomes were evaluated at baseline and at week 8 by means of an 11-point (0-10) numerical rating scale (NRS), the Pittsburgh Sleep Quality Index (PSQI), and the EuroQol health-state visuoanalogic scale (EQ-5D VAS) score, respectively. RESULTS: At week 8, mean PGB dose was 166.7 ± 7.8 mg/d. Pain intensity NRS score, PSQI total score, and EQ-5D VAS score were improved by 66.5% ± 1.9%, 40.0% ± 3.6%, and 26.4% ± 4.7% (all P < 0.01), respectively. Correlations between percent change from baseline in pain NRS score and PSQI total score or EQ-5D VAS scores were r = 0.36 (P < 0.01, R = 0.11) and r = -0.20 (P < 0.02, R = 0.05), respectively. A multivariate logistic regression analysis disclosed that PSQI score change below the median (ie, a better outcome) was related to higher EQ-5D VAS score change (odds ratio, 2.15; 95% confidence interval, 1.09-4.25), whereas pain intensity NRS score change below the median was not (odds ratio, 1.58; 95% confidence interval,0.78-3.23). CONCLUSIONS: In our study, PGB-related improvements in sleep quality and HRQoL were marginally related to reductions in pain intensity in patients with neuropathic pain. Improvement in sleep quality was a significant predictor of better HRQoL, whereas pain intensity reduction was not.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Lippincott Williams
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
HEALTH-RELATED QUALITY OF LIFE
dc.subject
PAIN
dc.subject
PREGABALIN
dc.subject
SLEEP QUALITY
dc.subject.classification
Fisiología
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Básica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an 8-week treatment course
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2023-04-20T12:39:10Z
dc.journal.volume
35
dc.journal.number
1
dc.journal.pagination
21-24
dc.journal.pais
Estados Unidos
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Philadelphia
dc.description.fil
Fil: Perez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Université Paul Sabatier; Francia
dc.description.fil
Fil: Rojas, Gloria Meza. Instituto Mutual de la Salud; Paraguay
dc.description.fil
Fil: Menoni, Maria Celia. Hospital Central. Servicio de Endocrinología y Metabolismo; Paraguay
dc.description.fil
Fil: Ruiz, Gabriela. Centro Médico Santa Clara; Paraguay
dc.description.fil
Fil: Velásquez, Carolina. Instituto Mutual de la Salud; Paraguay
dc.description.fil
Fil: Rodriguez, Hernán. Centro Médico Santa Clara; Paraguay
dc.description.fil
Fil: Rey, María Verónica. Université Paul Sabatier; Francia
dc.description.fil
Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina
dc.journal.title
Clinical Neuropharmacology
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://journals.lww.com/clinicalneuropharm/Abstract/2012/01000/Pregabalin_Beneficial_Effects_on_Sleep_Quality_or.4.aspx
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1097/WNF.0b013e31823df2dc
Archivos asociados